Skip to main content
Case Reports in Immunology logoLink to Case Reports in Immunology
. 2021 Jan 31;2021:2361360. doi: 10.1155/2021/2361360

Erratum to “Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome”

Cesar Daniel Alonso-Bello 1,, María del Carmen Jiménez-Martínez 2, María Eugenia Vargas-Camaño 1, Sagrario Hierro-Orozco 3, Mario Alberto Ynga-Durand 4, Laura Berrón-Ruiz 5, Julio César Alcántara-Montiel 6, Leopoldo Santos-Argumedo 6, Diana Andrea Herrera-Sánchez 1, Fernando Lozano-Patiño 1, María Isabel Castrejón-Vázquez 1
PMCID: PMC7895602  PMID: 33628541

In the article titled “Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome” [1], authors Mario Alberto Ynga-Durand and Julio César Alcántara-Montiel were affiliated to “Universidad Nacional Autónoma de Mexico, Facultad de Estudios Superiores Zaragoza, Facultad de Medicina, Mexico,” which is incorrect.

The correct affiliation of Mario Alberto Ynga-Durand is “Laboratorio de Inmunidad de Mucosas, Sección de Investigación y Posgrado, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City, Mexico.” The correct affiliation for Julio César Alcántara-Montiel is “Department of Molecular Biomedicine, CINVESTAV-IPN, Mexico City, Mexico.”

The error was introduced during the production process of the article, and Hindawi apologises for causing this error in the article.

The corrected list of affiliations is shown in the authors' information above.

References

  • 1.Alonso-Bello C. D., Jiménez-Martínez M. d. C., Vargas-Camaño M. E., et al. Partial and Transient Clinical Response to Omalizumab in IL-21-Induced Low STAT3-Phosphorylation on Hyper-IgE Syndrome. Case Reports in Immunology. 2019;2019:5. doi: 10.1155/2019/6357256.6357256 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Case Reports in Immunology are provided here courtesy of Wiley

RESOURCES